Literature DB >> 22868386

Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer.

Sarah L Picardo1, Stephen G Maher, Jacintha N O'Sullivan, John V Reynolds.   

Abstract

Cancer-related inflammation is considered the 'seventh hallmark of cancer'; many studies show that tumours develop and progress within inflammatory diseases. This review focuses on Barrett's oesophagus, a common condition in which chronic inflammation and resulting alterations in the stroma can lead to carcinogenesis, specifically oesophageal adenocarcinoma. Changes that occur in the tissue microenvironment during development of this disease are discussed. Infiltration of immune cells facilitates tumour development through production of factors that promote carcinogenesis and by enabling tumours to evade the host immune response. Small molecules including cytokines, chemokines and growth factors play key roles in both inflammation and cancer by promoting proliferation, angiogenesis and carcinogenesis and by recruiting immune cells. The extracellular matrix is altered in inflammation, and provides structural support to developing tumours. Hypoxia is a common state in cancers and inflamed tissues which causes DNA damage and induces tumourigenic factors. Finally, tissue vasculature is a vital part of its microenvironment, supplying oxygen, nutrients and growth factors to rapidly dividing cells, and providing a mechanism for metastatic spread. The cells and molecules outlined here represent potential targets for treatment of this cancer, especially in its pre-cancerous, inflammatory stage.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22868386     DOI: 10.1159/000341498

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  36 in total

1.  Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study.

Authors:  Panagiotis Tsibouris; Mark T Hendrickse; Panagiota Mavrogianni; Peter Et Isaacs
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 2.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 3.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

4.  Serum Glycoprotein Biomarker Discovery and Qualification Pipeline Reveals Novel Diagnostic Biomarker Candidates for Esophageal Adenocarcinoma.

Authors:  Alok K Shah; Kim-Anh Lê Cao; Eunju Choi; David Chen; Benoît Gautier; Derek Nancarrow; David C Whiteman; Nicholas A Saunders; Andrew P Barbour; Virendra Joshi; Michelle M Hill
Journal:  Mol Cell Proteomics       Date:  2015-09-24       Impact factor: 5.911

5.  Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study.

Authors:  Hashem B El-Serag; Ali Hashmi; Jose Garcia; Peter Richardson; Abeer Alsarraj; Stephanie Fitzgerald; Marcelo Vela; Yasser Shaib; Neena S Abraham; Maria Velez; Rhonda Cole; Margot B Rodriguez; Bhupinderjit Anand; David Y Graham; Jennifer R Kramer
Journal:  Gut       Date:  2013-02-13       Impact factor: 23.059

Review 6.  Heparanase in inflammation and inflammation-associated cancer.

Authors:  Amichay Meirovitz; Rachel Goldberg; Adi Binder; Ariel M Rubinstein; Esther Hermano; Michael Elkin
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

7.  HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.

Authors:  Ashwini Gowryshankar; Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2014-02

8.  Loss of glutathione peroxidase 7 promotes TNF-α-induced NF-κB activation in Barrett's carcinogenesis.

Authors:  Dun-Fa Peng; Tian-Ling Hu; Mohammed Soutto; Abbes Belkhiri; Wael El-Rifai
Journal:  Carcinogenesis       Date:  2014-04-01       Impact factor: 4.944

9.  Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium.

Authors:  Michael B Cook; Matthew J Barnett; Cathryn H Bock; Amanda J Cross; Phyllis J Goodman; Gary E Goodman; Christopher A Haiman; Kay-Tee Khaw; Marjorie L McCullough; Christine C Newton; Marie-Christine Boutron-Ruault; Eiliv Lund; Martin Rutegård; Mark D Thornquist; Michael Spriggs; Carol Giffen; Neal D Freedman; Troy Kemp; Candyce H Kroenke; Loïc Le Marchand; Jin Young Park; Michael Simon; Lynne R Wilkens; Ligia Pinto; Allan Hildesheim; Peter T Campbell
Journal:  Gut       Date:  2018-08-18       Impact factor: 23.059

Review 10.  The tumour immune microenvironment in oesophageal cancer.

Authors:  Maria Davern; Noel E Donlon; Margaret R Dunne; Robert Power; Conall Hayes; Ross King; John V Reynolds
Journal:  Br J Cancer       Date:  2021-04-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.